FDA, Tirzepatide

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...
Tirzepatide, the active ingredient in both Mounjaro for type 2 diabetes and Zepbound for weight loss, was in short supply for ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
Harvey Fierstein shared how he lost 120 pounds. He says he is a “great believer” in weight loss drugs like Zepbound and ...
In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...